Omalizumab for the treatment of chronic inducible urticaria in 80 patients
V. Expósito‐Serrano, Laia Curto‐Barredo, P. Aguilera Peiro, S. Gómez Armayones, E. Serra‐Baldrich, Jorge Spertino, Montserrat Bonfill Ortí, Ignasi Figueras‐Nart, Gemma Melé‐Ninot, Carola Baliu‐Piqué, Anna Sala Cunill, Moisés Labrador‐Horrillo, A. Guilabert Vidal, Natalia Fernández Chico, Ana M. Giménez‐Arnau
Abstract
Email: [email protected] Funding sources: no external funding. Conflicts of interest: except for P.A.P., S.G.A. and C.B.‐P., all authors have received funds from Novartis as follows: V.E.‐S., M.B.O., G.M.‐N. and N.F.C.: lecture fees and educational activities; L.C.‐B., E.S.‐B., J.S., M.L.‐H. and A.S.C.: lectures including service on speakers’ bureaus and consultancy; I.F.N.: speaker honorarium and attending congresses; A.G.V.: honoraria for the development of educational activities; A.M.G.‐A.; as medical advisor, also research grants and educational activities. Dear Editor, An observational retrospective multicentre study was conducted by the Catalan and Balearic Urticaria Network (XUrCB). We recruited 80 participants with conditions as follows: solar urticaria (n = 27), cold urticaria (n = 22), symptomatic dermographism (n = 11), cholinergic urticaria (n = 10), delayed pressure urticaria (n = 7), aquagenic urticaria (n = 2) and heat urticaria (n = 1). To compare the therapeutic benefits for different subtypes of chronic inducible urticaria (CIndU), we evaluated response to omalizumab 300 mg per 4 weeks using the urticaria control test (UCT),1 grouping patients according to response [complete response (UCT = 16), satisfactory response (UCT ≥ 12–15) and nonresponse (UCT < 12)]. We also analysed time to a satisfactory/complete response (fast ≤ 3 months and slow > 4 months). We used omalizumab according to the EAACI/GA2LEN/EDF/WAO guideline recommendations.2 We used multivariate statistical analysis to evaluate the factors that could predict response: sex, age, body mass index, years with CIndU, personal atopy history, previous CIndU episodes, personal angio‐oedema history, baseline total IgE (normal value ≤ 104 kU L–1), baseline D‐dimer (normal value ≤ 500 ng mL–1) and baseline UCT. The study was approved by our Clinical Research Ethics Committee (2016/6606/IEUDRAC).